Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-45 and CD45BE-HSPC in Relapsed/Refractory Hematologic Malignancies
NCT07451054Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Aug 2026
- Primary completion
- Jul 2051
- Modality
- CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-45 in B-cell non-Hodgkin lymphoma, Richter's transformation (RT), T-cell non-Hodgkin lymphoma and 1 more (2 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Incidence of Adverse Events at 15 years, Occurrence of dose-limiting toxicities at 28 days and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
CART-45
03
Conditions
B-cell non-Hodgkin lymphomaRichter's transformation (RT)T-cell non-Hodgkin lymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT07451054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451054.